Taiwan Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform, leveraging capital-efficient strategies and Taiwan’s robust talent pool to challenge global standards in metabolic health and chronic disease management. …
Switzerland For a tiny Alpine nation nestled deep in the interior of continental Europe, Switzerland boasts a spectacularly vibrant biotech scene. This is because “the country manages to leverage its compact geography to achieve unprecedented levels of collaboration across key innovation hubs, rendering it possible to forge strong networks and partnerships…
China A roundup of some ot the biggest stories coming out of China’s biopharma industry: Chinese pharma shifts to local reagent suppliers; WuXi Biologics launches new stable cell line platform; Fosun and Expedition Therapeutics ink respiratory licensing deal, and GSK lands USD 500 million 12-drug agreement with Hengrui Pharma. China…
Switzerland Riad Sherif, CEO of Oculis, leads strategic innovation in ophthalmology and neuro-ophthalmology. With over 25 years of global experience, he has built a highly differentiated late-stage pipeline focused on addressing unmet medical needs through visionary innovations. Under his leadership, Oculis has grown from a hospital project with a single asset…
Switzerland Stefan Schmidt traces a dynamic career from early biotech ventures in Germany to senior leadership roles at AstraZeneca, Lonza, and now CEO of evitria, a specialised Swiss CRO focused on complex antibody development. Evitria is expanding its technology and global reach to become a key partner in bispecific and engineered…
China Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and no initial products, OcuMension now leads in China’s ophthalmology drug development, maintains rapid growth, and is preparing for global reach.…
Puerto Rico We’re not just building facilities—we’re building the future of medicine, where innovation is inclusive, access is equitable, and every breakthrough brings us closer to a healthier world. Biopharmaceutical innovation is advancing rapidly, yet inefficiencies in development and manufacturing continue to slow progress. OcyonBio, under the leadership of CEO Robert Salcedo,…
Brazil A roundup of the biggest stories from Brazil’s pharma industry, including Teuto’s cannabis manufacturing deal with MediPharm; Eurofarma’s AI-based epilepsy joint venture with SK Biopharmaceuticals; EMS’s increased stake in Hypera after a failed merger attempt, and Quantoom, Univercells and Fiocruz’s RNA-based vaccine production collaboration. MediPharm Labs Enters Landmark Commercial…
China The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from Roche and CytoNiche Biotechnology’s new R&D centre. COVID global emergency over but risks remain, says China health official (Reuters)…
China In light of ongoing geopolitical tension, a globally unfavourable macroeconomic environment and new drug-pricing legislation in the US, at the recent BIO CEO and Investor Conference industry stakeholders evaluated the risks and the opportunities for cross-border deal-making between US and China and found a number of reasons to be optimistic.…
China A roundup of some of the biggest pharma and biotech news from China including the approval of two domestically developed COVID treatments; Daewoong’s idiopathic pulmonary fibrosis licensing deal, Roche’s gastric cancer partnership with CARsgen; Sino Biopharm’s continued attempt to buyout of F-star Therapeutics and Takeda’s deal with Hutchmed for a…
China A roundup of some of the biggest recent stories from Chinese pharma, including Moderna’s refusal to divulge its mRNA IP, Advanced MedTech’s acquisition of urology leader WIKKON and Menarini’s AMR deal with SciClone Pharmaceuticals. Moderna holds onto its vaccine IP and refuses tech transfer in China (Financial Times) Moderna…
See our Cookie Privacy Policy Here
